|
|||||
|
|
Effectiveness of Elbasvir and Grazoprevir Combination,With or Without Ribavirin,for Treatment-Experienced Patients With Chronic Hepatitis C Infection |
|
| Authors: | Paul Kwo Edward J. Gane Cheng-Yuan Peng Brian Pearlman John M. Vierling Lawrence Serfaty Maria Buti Stephen Shafran Paul Stryszak Li Lin Jacqueline Gress Stuart Black Frank J. Dutko Michael Robertson Janice Wahl Lisa Lupinacci Eliav Barr Barbara Haber |
| Affiliation: | 1. Indiana University, Indianapolis, Indiana;2. Auckland Clinical Studies, Grafton, Auckland, New Zealand;3. School of Medicine, China Medical University, Taichung, Taiwan;4. Center for Hepatitis C, Atlanta Medical Center, Atlanta, Georgia;5. Baylor College of Medicine, Baylor-St. Luke''s Medical Center, Houston, Texas;6. Service d’Hépatologie, Hôpital Saint-Antoine, APHP, UPMC Paris 6, Paris, France;7. Hospital Universitari Vall d''Hebron, and Ciberehd del Instituto Carlos III, Barcelona, Spain;8. University of Alberta, Edmonton, Alberta, Canada;9. Merck & Co, Inc, Kenilworth, New Jersey |
| Abstract: | |
| Keywords: | Hepatitis C Randomized Therapy C-EDGE Treatment-Experienced AE adverse event ALT alanine aminotransferase ART antiretroviral therapy CI confidence interval EBR elbasvir GT genotype GZR grazoprevir HCV hepatitis C virus HIV human immunodeficiency virus NGS next-generation sequencing PR peginterferon/ribavirin RAV resistance-associated variant RBV ribavirin SAEs serious adverse events ST sensitivity threshold SVR sustained virologic response 12 weeks after completion of treatment |
| 本文献已被 ScienceDirect 等数据库收录！ | |